Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months

BACKGROUND. We report updated safety, efficacy, and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) from an ongoing phase 3 trial. METHODS. Adults at increased risk of SARS-CoV-2 infection were randomized (2:1), stratified by age, to receive 2 doses of AZD1222 or placebo. The primary efficacy end point...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The Journal of clinical investigation 2022-09, Vol.132 (18), p.1-14
Hauptverfasser:	Sobieszczyk, Magdalena E, Maaske, Jill, Falsey, Ann R, Sproule, Stephanie, Robb, Merlin L, Frenck, Robert W, Tieu, Hong-Van, Mayer, Kenneth H, Corey, Lawrence, Neuzil, Kathleen M, Tong, Tina, Isaacs, Margaret Brewinski, Janes, Holly, Bansal, Himanshu, Edwards, Lindsay M, Green, Justin A, Kelly, Elizabeth J, Shoemaker, Kathryn, Takas, Therese, White, Tom, Bhuyan, Prakash, Villafana, Tonya, Hirsch, Ian
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomedical research Coronaviruses COVID-19 vaccines Immune response (humoral) Immunogenicity Placebos Population Severe acute respiratory syndrome coronavirus 2 Thrombocytopenia Thrombosis Vaccination Vaccine efficacy Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!